Premium
The clinical effect of the GABA‐agonist, progabide, on spasticity
Author(s) -
Mondrup Kurt,
Pedersen Ejner
Publication year - 1984
Publication title -
acta neurologica scandinavica
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.967
H-Index - 95
eISSN - 1600-0404
pISSN - 0001-6314
DOI - 10.1111/j.1600-0404.1984.tb07802.x
Subject(s) - spasticity , spastic , anesthesia , placebo , medicine , hypertonia , multiple sclerosis , physical therapy , cerebral palsy , alternative medicine , pathology , psychiatry
— In a double‐blind cross‐over trial of two 2‐week periods, the clinical effect of progabide was compared to placebo. 16 patients with spasticity in a stationary phase completed the trial. 14 had multiple sclerosis, 2 hereditary spastic paraplegia. 5 were female and 11 male. The median age was 45.5 years (range 30–62 years). The median daily dosage of progabide was 24.3 mg/kg (range 14.3–32.7 mg/kg). During progabide treatment, there was a reduction in spastic hypertonia ( P < 0.01), a suppression of tendon reflexes (patellar) ( P < 0.01), and a reduction in the frequency of flexor spasms ( P < 0.05). No significant changes in voluntary power were registered. The global clinical impression revealed a therapeutic effect in 87% of the patients (95% confidence limits 61–98%). The improvement was judged as medium or important in 50% of the patients (95% confidence limits 23–77%). No side‐effects or laboratory abnormalities were seen.